News

Altrazeal, a wound treatment technology, has shown clinical and economic advantages in a number of chronic and acute wounds, which include diabetic foot ulcers, venous leg ulcers and

The acquisition follows the previously announced asset purchase agreement. WBI-1001 is a non-steroidal, topical anti-inflammatory new chemical entity (NCE) agent, which has demonstrated efficacy and safety in Ph1

Migraine Patch (NP101 or Zelrix) is an active, single-use, transdermal patch in the development process to treat migraine. NuPathe has received a Prescription Drug User Fee Act (PDUFA)

The move follows the directives from the Food and Drug Administration. HA personnel manager T Das was quoted by The Indian Express as saying that HA stalled the

The treatment with oral, selective p38 inhibitor, resulted in a statistically significant reduction in pain over a 28-day period compared to placebo, as measured using the Western Ontario

The NIH exclusive license covers composition and uses of RCT1938 worldwide as a radiosensitizer to treat cancer and to treat or prevent radiation exposure in humans. RCT1938 is

The license agreement with Menarini include the commercialization of Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Priligy, which is indicated for the

According to the agreement, Oncobiologics will have access to XOMA’s diverse library of single-chain variable fragments antibodies and associated patent estate, and will utilize XOMA’s know-how and proven

The US patent no. 8,173,072 describes the conversion of nitrogen dioxide (NO2) to nitric oxide (NO), using the GeNO cartridge technology, in a gas stream to treat acute